Educational Videos

ACR/VF Guidelines Conference Videos

General Session One: Part 1
Introducing the 2021 ACR/VF Vasculitis Clinical Practice Guidelines

Speaker:
Sharon A. Chung, MD, MAS
Director, Vasculitis Clinic, UCSF
San Francisco, California

General Session One: Part 2
Introducing the 2021 ACR/VF Vasculitis Clinical Practice Guidelines: Q&A with Dr. Sharon Chung

General Session Two: Disseminating the Guidelines to Healthcare Professionals

Speaker:
Carol A. Langford, MD, MHS, FACP
Director, Center for Vasculitis Care and
Research, Cleveland Clinic, Cleveland, Ohio

2021 Virtual ACR/VF Patient Treatment Conference Breakout Sessions

Giant Cell Arteritis (GCA) Breakout Session

Historical Accounts of GCA 4:02
2012 Revised International Chapel Hill Consensus Conference (CHCC2012) Nomenclature of Vasculitides 5:28
CHCC2012 definition of GCA 6:41
Therapy Definitions 8:56
GCA Case: Initial Presentation 11:09
Diagnostic Testing Recommendations 14:17
Medical Management Recommendations 26:29
Trial of Tocilizumab in GCA 31:44
GCA Case: New Visual Symptoms 34:18
Surgical Intervention Recommendations 38:00
GCA Case: The Challenge of Inflammatory Markers 40:47
Clinical / Laboratory Monitoring Recommendations 41:43
GCA Case: Relapse 42:26
Medical Management Recommendations: Add Statins? 46:00
GCA Case: Long Term Monitoring 48:12
Duration of Therapy Upgraded Position Statement 49:50

Speaker:
Mehrdad Maz, MD
Director, Allergy, Clinical Immunology
and Rheumatology, Kansas University,
Kansas City, Kansas

Moderator:
Rennie Rhee, MD,
University of Pennsylvania Vasculitis Center,
Philadelphia, Pennsylvania

Polyarteritis Nodosa (PAN) Breakout Session

Polyarteritis Nodosa (PAN) Quick Facts 2:41
Important Considerations for the Recommendations 6:40
Guideline Methods 7:39
PAN Case One 9:56
Diagnostic Challenges: The Skin Biopsy 10:32
Skin Biopsy: Deep vs. Punch 11:45
Diagnostic Challenges: The Nerve Biopsy 13:24
Abdominal Vascular Imaging 17:24
Treatment Phases 20:15
Treatment After Remission 22:29
Treatment with Physical Therapy 24:59
Q&A: Do these guidelines cover systemic and cutaneous PAN? 30:40
Q&A: Do the recommendations cover the use of Rituximab with PAN? 31:29
Q&A: Was it a challenge to find clinical study information on PAN to use in considering recommendations? 35:43
Q&A: What is recommendation if patient fails Cellcept and is having a liver problem? Is Rituximab an option? 38:49
Q&A: What do recommendations say about how long a patient has to remain on immunosuppressants or steroids once he/she is in remission? 42:27
Q&A: Could you share the 2-3 most important recommendations for PAN? 45:16
Q&A: Do the recommendations address the issue of using imaging to monitor long-term damage caused to the arteries. 48:32

Speaker:
Jason A. Springer, MD, MS
Co-Director, Vanderbilt Vasculitis Center,
Nashville, Tennessee

Moderator:
Yih Chang Lin, MD
University of South Florida Vasculitis Center
Tampa, Florida

Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Breakout Session

Overview of GPA and MPA 1:56
A Patient Case 4:07
General Treatment Strategy: active, severe GPA/MPA 5:48
Question: What medication should this patient receive for remission induction? 6:59
Reduced vs. Standard Dosing Regimen 10:16
What About Other Remission Maintenance Agents? 15:14
Preferences for Remission Induction and Maintenance Therapy in Severe GPA/MPA 16:29
What Therapy If Relapse Occurs? 25:14
What About ANCA Titers? 28:06
What About Combination Drive? 35:35
Other Interventions About Sinus Symptoms? 37:41
Avacopan. 39:44
Q: Could you talk more about ANCA-titers, and B-Cell Monitoring? 44:51
Q: What research or knowledge gaps did you find related to GPA and MPA? 51:23
Q: Do the ACR/VF Guidelines address biosimilars? 53:42
Q: Any comments or concerns about the COVID vaccines triggering an autoimmune response? 54:54

Speaker:
Sharon A. Chung, MD, MAS Director, Vasculitis
Clinic, UCSF
San Francisco, California

Moderator:
Kevin W. Byram, MD
Co-Director, Vanderbilt Vasculitis Clinic,
Nashville, Tennessee

Eosinophilic Granulomatosis with Polyangiitis (EGPA) Breakout Session

Overview of EGPA 2:10
ACR / VF Guideline for the Management of EGPA 3:25
Recommendations on the Treatment of EGPA 5:03
Q&A: Is being ANCA negative a good thing, or a bad thing? 19:44
Q&A: Could you comment on what the guidelines say about Leukotriene inhibitors? 22:24
Q&A: What is the role for Avocopan in EGPA? 24:00
Q&A: Can you comment on the recommendation about having an echocardiogram at the time of diagnosis? 27:48
Q&A: Do the guidelines take a stand on the use of Mepolizumab? Is this the drug of choice? 30:59
Q&A: Are there still patients for whom you would recommend the use of Cyclophosphamide over Rituximab? 32:47
Q&A: Do you have a favorite guideline? 35:10
Q&A: Do you think there are particular guidelines that will be ripe of review in the future? 37:25
Q&A: Do you have an opinion on the role of IVIG and whether it’s indicated, or contradicted in EGPA? 39:08
Q&A: Can you comment on the role of pneumocystis prophylaxis?
Q&A: What do you see as the most urgent clinical need for EGPA? 45:14
Q&A: If a patient has EGPA is there any concern that someone else in their family could also get it, or a form of vasculitis? 46:14
Q&A: Do all flares in EGPA associate with increases in eosinophils count? 49:23

Speaker:
Carol A. Langford, MD, MHS, FACP
Director, Center for Vasculitis Care and
Research, Cleveland Clinic, Cleveland, Ohio

Moderator:
Phil Seo, MD
Director, Johns Hopkins Vasculitis Center,
Baltimore, Maryland

NOTE: The Concurrent Breakout Sessions were recorded and they will be available here in the near future.